{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:51:59Z","timestamp":1763754719094,"version":"3.45.0"},"reference-count":13,"publisher":"Oncology Nursing Society (ONS)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2012,2,1]]},"DOI":"10.1188\/12.cjon.86-89","type":"journal-article","created":{"date-parts":[[2012,2,2]],"date-time":"2012-02-02T22:55:45Z","timestamp":1328223345000},"page":"86-89","source":"Crossref","is-referenced-by-count":8,"title":["Bortezomib-Induced Peripheral Neuropathy in Patients With Multiple Myeloma"],"prefix":"10.1188","volume":"16","author":[{"given":"Anne","family":"Berkowitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Walker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2012,2,1]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: A comprehensive review of the literature","volume":"112","author":"A. Argyriou","year":"2008","journal-title":"Blood"},{"key":"2","first-page":"1042","article-title":"Neurotoxicity of bortezomib therapy in multiple myeloma: A single-center experience and review of the literature","volume":"110","author":"A. Badros","year":"2007","journal-title":"Cancer"},{"key":"3","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3109\/10428194.2010.483303","article-title":"Peripheral neuropathy during bortezomib treatment of multiple myeloma: A review of recent studies","volume":"51","author":"G. Cavaletti","year":"2010","journal-title":"Leukemia and Lymphoma"},{"key":"4","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1470-2045(10)70068-1","article-title":"Treatment-related peripheral neuropathy in multiple myeloma: The challenge continues","volume":"11","author":"M. Delforge","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/SPC.0b013e328342f9cc","article-title":"Chemotherapy-induced neuropathic pain","volume":"5","author":"P. Farquhar-Smith","year":"2011","journal-title":"Current Opinion in Supportive and Palliative Care"},{"key":"6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/2042018810391900","article-title":"Clinical approach to the treatment of painful diabetic neuropathy","volume":"2","author":"A. Hovaguimian","year":"2011","journal-title":"Therapeutic Advances in Endocrinology and Metabolism"},{"key":"7","unstructured":"Millennium Pharmaceuticals, Inc. (2011). <i>Velcade\u00ae (bortezomib)<\/i> [Package insert]. Retrieved from <a target=\"_blank\" href='http:\/\/www.velcade.com\/Files\/PDFs\/VELCADE_PRESCRIBING_INFORMATION.pdf'>http:\/\/www.velcade.com\/Files\/PDFs\/VELCADE_PRESCRIBING_INFORMATION.pdf<\/a>"},{"key":"8","unstructured":"National Cancer Comprehensive Network. (2011). <i>NCCN Clinical Practice Guidelines in Oncology: Multiple myeloma<\/i> [v.1.2012]. Retrieved from <a target=\"_blank\" href='http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf'>www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf<\/a>"},{"key":"9","unstructured":"National Cancer Institute Cancer Therapy Evaluation Program. (2010). <i>Common terminology criteria for adverse events<\/i> [v.4.0]. Retrieved from <a target=\"_blank\" href='http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm'>http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm<\/a>"},{"issue":"1","key":"10","article-title":"Complications of multiple myeloma therapy, part 1: Risk reduction and management of peripheral neuropathy and asthenia","volume":"8","author":"P. Richardson","year":"2010","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"11","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial","volume":"110","author":"P. Richardson","year":"2007","journal-title":"Blood"},{"issue":"5","key":"12","article-title":"NCCN task force report: Management of neuropathy in cancer","volume":"7","author":"M. Stubblefield","year":"2009","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"3","key":"13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1188\/08\/CJON.SI.29-35","article-title":"Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: Consensus statement of the IMF Nurse Leadership Board","volume":"12","author":"J. Tariman","year":"2008","journal-title":"Clinical Journal of Oncology Nursing"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/B000152741528012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:48:07Z","timestamp":1763754487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/16\/1\/bortezomib-induced-peripheral-neuropathy-patients-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2,1]]}},"alternative-id":["B000152741528012"],"URL":"https:\/\/doi.org\/10.1188\/12.cjon.86-89","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2012,2,1]]}}}